Pfizer Inc. on Tuesday raised its forecast for annual sales of its COVID-19 vaccine by $2 billion to $34 billion on demand for Omicron-targeted boosters, helping allay some investor worries over growth for the vaccinations.
Eli Lilly and Co. on Tuesday forecast its annual profit and revenue below estimates, as a stronger dollar piled more pressure on the drugmaker struggling with lower insulin prices and generic competition for its cancer drug.
Pfizer Inc. said on Tuesday its experimental respiratory syncytial virus (RSV) vaccine was found effective for preventing severe infections in infants after being given in a late-stage study to expectant mothers in the second half of pregnancy.
While reporting positive third-quarter financials, AbbVie announced it is halting the development of cedirogant (ABBV-157), while also providing updates on Skyrizi, Rinvoq and Humira.
CytoDyn withdrew its pending Biologics License Application for the monoclonal antibody in HIV Friday, citing concerns involving the contract research organization managing its trials.
Platform technology company Replay has launched Eudora, a gene therapy company targeting genetic diseases of the retina.
China has blocked GSK from participating in its national bulk-buy drug procurement program from Oct. 31 until April 29, 2024 over quality problems with a prostate drug, the British drugmaker said on Monday.
Thermo Fisher Scientific Inc said it would buy Binding Site Group from European private equity firm Nordic Capital in an all-cash transaction valued at 2.25 billion pounds ($2.6 billion), boosting its specialty diagnostics business.
Since mid-October, Foxconn has been wrestling with a COVID-19 outbreak at its facility in Zhengzhou, the capital of Henan province in central China.
Indonesia’s food and drug agency (BPOM) said on Monday it had revoked licenses of syrup-type drug production of two local firms for violating manufacturing rules, as it probes the deaths of more than 150 children due to acute kidney injury (AKI).